AstraZeneca (AZN)
(Delayed Data from NSDQ)
$76.87 USD
0.00 (0.00%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $76.86 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth B Momentum C VGM
Price, Consensus and EPS Surprise
AZN 76.87 0.00(0.00%)
Will AZN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for AZN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AZN
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
AZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
ONCY Stock Up on Regulatory Update From Breast Cancer Program
5 Large Drug Stocks to Watch From a Thriving Industry
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
Other News for AZN
Protean Funds Scandinavia AB September 2024 Partner Letter
Best Ideas From Quality Growth Investor Conference In London
AstraZeneca deal has positive read for Silence Therapeutics, says Morgan Stanley
Arcus a new overweight at Wells Fargo on potential of casdatifan in kidney cancer
Goldman Sachs Sticks to Its Buy Rating for AstraZeneca (AZN)